

## SUBJECT INDEX VOLUME 2

Achalasia .....	179	due to osteoblastoma .....	281
Adolescents .....	120	due to osteosarcoma .....	282
Adolescents' sexual health .....	369	due to slipped vertebral apophysis .....	280
implication for pediatric practice .....	371	due to spinal cord injury without radiographic	
Airway patency .....	339	abnormality (SCIWORA) .....	280
in children .....	339	due to spinal trauma in child abuse .....	280
Antiepileptic drugs .....	85	epidemiology of .....	265
endocrine abnormalities induced by .....	85	etiology of .....	265
Anti-phospholipid syndrome .....	169	history of .....	266
management in .....	169	imaging studies of .....	268
Appendicitis .....	347	in adolescents .....	265
diagnosis of .....	347	in children .....	265
in infancy .....	347	laboratory tests in .....	270
Arterial hypertension .....	209	physical examination in .....	267
basic science studies in .....	210	scheuermann's disease of .....	270
cardiac output in .....	210	treatment for .....	265
clinical studies in .....	211	Biliary atresia (BA) .....	351
endothelin in .....	217	diagnosis of .....	354
genetic factors in .....	219	etiology of .....	352
natriuretic peptide family in .....	217	long term outcome of .....	356
nitric oxide in .....	218	pathophysiology of .....	351
pathophysiology of .....	209	Blood pressure regulation .....	211
pediatric studies of .....	209	control by central nervous system areas.....	211
physiological determinants of blood pressure in ...	210	effect of baroreceptor reflex .....	211
Arterial ischemic stroke (AIS) .....	301	effect of kallikrein-kinin system .....	216
acute treatment for .....	306	effect of sympathetic nervous overactivity .....	212
diagnosis of .....	304	endothelin in .....	217
due to arteriopathies .....	302	humoral and local regulators of .....	214
due to cardiac disorders .....	303	natriuretic peptide family in .....	217
due to prothrombotic/haematological disorders ...	303	neural mechanisms of .....	211
etiologies of .....	303	nitric oxide in .....	218
in children .....	301	renal mechanisms of .....	213
in neonates .....	301	Brachycephaly .....	33
neuroimaging of .....	304	Bronchodilation .....	341
pathophysiology of .....	301	effect of elasticity of airways/lung .....	341
prevention for .....	306	Carotid body chemosensitivity .....	200
rehabilitation for .....	308	Carotid body's neurotransmitter systems .....	201
risk factors for .....	301	developmental changes in .....	201
treatment for .....	306	environmental factors .....	201
Attention deficit hyperactivity disorder (ADHD) .....	17	Cerebral hypoxic-ischemic injury .....	131
alpha activity in .....	24	by cytosolic calcium .....	137
beta activity in .....	23	by deficiencies in energy supply .....	134
changes in eeg power distributions related to .....	21	by genes .....	138
children with symptoms of .....	17	by inflammatory mediators .....	137
diagnostic methods of .....	17	by necrosis/apoptosis .....	138
electroencephalographic profiles of .....	17	by nitric oxide .....	136
etiology of .....	18	by reactive oxygen species/free radicals .....	134
theta activity in .....	22	by transcription factors activation .....	138
Back pain .....	265	cellular bases of .....	132
clinical approach to .....	265	Chemokines .....	3
due to aneurismal bone cyst (ABC) .....	281	in asphyxia .....	9
due to benign neoplasms .....	280	in neonatal brain damage .....	9
due to fractures of spine .....	279	Chemoreceptor cells .....	200
due to langerhans' cell histiocytosis .....	281	developmental changes in biophysical properties .	200
due to leukemia .....	282	Chest pain .....	245
due to malignant tumors .....	282	chest wall pain as .....	248
due to neoplasms .....	280		

clinical evaluation of .....	254	CDG-x as .....	327
epidemiology of .....	245	diagnostic strategies for .....	323
etiologies of .....	248	first lipid glycosylation disorders as .....	327
history-taking in .....	256	hyperglycosylation disorders as .....	327
in children .....	245	<i>N/O</i> -glycosylation as .....	326
management of .....	257	types of .....	326
mediastinal pain as .....	248	Critical illness .....	233
physical examination in .....	256	body composition tests in .....	240
pleural pain as .....	248	energy expenditure in .....	239
Childhood asthma .....	155	immunity – exercise tolerance in .....	241
drug therapy for .....	156	in clinical assessment .....	235
prevention of irreversible loss of lung function in .....	161	neurohumoral activation in .....	233
treatment of .....	155	nutritional status/care plan in .....	234
use of delivery devices .....	161	protein turnover in .....	236
Children .....	115	role of anthropometrics .....	235
1-4 years old .....	117	Cycle helmets .....	49
body composition of .....	116	for children .....	49
carbohydrates need in .....	118	in reducing injury .....	50
energy need in .....	116	methods of assessing efficacy of .....	49
fibre need in .....	119	standards for .....	51
fluid need in .....	119	Cystic fibrosis .....	107,99
lipid need in .....	118	docosahexaenoic acid in .....	107
minerals/micronutrients need in .....	119	essential fatty acids in .....	107
nutrient needs in .....	117	etiology of EFA imbalance in .....	109
nutritional needs for .....	115	gene therapy for .....	99
of 4-12 years .....	120	path of therapeutic gene in .....	101
physiologic needs of .....	116	role of fat .....	107
protein need in .....	117	Cystic fibrosis transmembrane conductance regulator	
Chronic granulomatous disease .....	63	(CFTR) .....	99
bone marrow transplantation in .....	71	expression of .....	102
clinical presentation of .....	65	topical/systemic delivery of .....	100
diagnosis of .....	68	Cytokines .....	3
gene therapy for .....	71	in neonatal brain damage .....	7
granulocyte instillation/trans-fusions in .....	70	in perinatal asphyxia .....	7
in childhood .....	63	in perinatal infections .....	7
infectious prophylaxis for .....	69	Deep inhalation (DI) .....	339
inflammatory complications in .....	67	airway responsiveness in .....	343
laboratory findings of .....	68	bronchoprotection by .....	339
management of infections in .....	69	health children .....	342
molecular basis of .....	65	implications for lung function testing .....	344
pathogens in .....	67	in children .....	339
recombinant human IFN- $\gamma$ .....	70	in growth/aging .....	343
treatment of inflammatory complications .....	71	Diskitis .....	276
Clinical practice .....	369	Docosahexaenoic acid .....	110
implications for .....	369	in CF mice .....	110
Community acquired pneumonia .....	331	in CF patients .....	110
chest x-ray/radiograph in .....	331	in cystic fibrosis .....	110
diagnosis .....	331	Electroencephalographic .....	17
in children .....	331	in ADHD diagnosis .....	19
Complementary and alternative medicine .....	361	Endocrinological side effects .....	85
definition by national center for .....	361	of benzodiazepines (BZDs) .....	85
definitions of .....	361	of carbamazepine (CBZ) .....	85
in biologically based therapies .....	363	of clobazam .....	85
in energy therapies .....	363	of ethosuximide (ETS) .....	86
in manipulative/body-based methods .....	363	of felbamate (FBM) .....	86
in pediatric oncology .....	361	of gabapentin (GBP) .....	86
Congenital disorders of glycosylation (CDG) .....	323	of lamotrigine (LTG) .....	86
CDG-Ia as .....	324	of levetiracetam (LEV) .....	87
CDG-Ic as .....	325	of oxcarbazepine (OXC) .....	87
CDG-Id as .....	325	of phenobarbital (PB) .....	87
CDG-IIf as .....	326		
CDG-IL as .....	326		

of phenytoin (PHT) .....	87	Hypoxic-ischemic reperfusion injury .....	41
of primidone (PRM) .....	88	deferorxamine in .....	43
of tiagabine (TGB) .....	88	erythropoietin in .....	43
of topiramate (TPM) .....	88	free radical formation due to .....	41
of valproic acid (VPA) .....	89	hypothermia .....	45
of vigabatrin (VTG) .....	90	intervention strategies to .....	46
of zonisamide (ZNS) .....	90	mechanisms of .....	41
Exogenous glucocorticoids .....	77	newborn brain of .....	41
effect on cutis/subcutis .....	81	nitric oxide synthase inhibition in .....	43
effects on cartilage .....	81	pharmacological treatment of .....	41
effects on linear bone growth .....	81	xanthine oxidase inhibition with allopurinol .....	44
effects on soft tissues .....	81	Idiopathic hypercalciuria .....	93
growth suppressive effects of .....	77	clinical manifestations of .....	93
knemometry for assessment of .....	77	decreased tubular Ca reabsorption .....	95
lower leg growth suppression by .....	81	epidemiology of .....	93
Facial injury .....	50	in children .....	93
Fatty acids .....	108	increased intestinal Ca absorption .....	94
in cystic fibrosis .....	108	increased osseous resorption .....	94
Fetal breathing movements (FBM) .....	290	pathogenetics of .....	94
Fetal lung liquid dynamics .....	288	pathophysiology of .....	94
Fetal pulmonary haemodynamics .....	287	treatment for .....	96
changes in .....	293	Imperforate anus .....	179
non-respiratory influences on .....	292	Inflammation .....	3
Fetal surgery .....	182	by hypoxia-ischaemia .....	5
Gastrointestinal surgery .....	178	by infections .....	3
appendectomy as .....	178	Intervertebral disk herniation .....	278
cholecystectomy as .....	178	Intra-luminal .....	287
fundoplication of .....	178	effect on pulmonary haemodynamics .....	289
gastrostomy as .....	178	Inulin .....	225
hepatobiliary surgery as .....	180	clearance of .....	225
in inguinal hernia .....	180	Knemometry .....	77
in undescended testis .....	180	of in glucocorticoid treatment .....	79
in urology .....	180	of inhaled glucocorticoids .....	79
in varicocele .....	180	of injected glucocorticoids .....	80
intestinal surgery as .....	180	of intranasal glucocorticoids .....	80
splenectomy as .....	178	of oral glucocorticoids .....	79
Global developmental delay (GDD) .....	143	of topical glucocorticoids .....	80
approach to child with .....	149	to analyse linear bone growth .....	78
clinical assessment of .....	145	to analyse lower leg growth .....	78
definition of .....	143	to analyse soft tissues .....	79
developmental screening/developmental surveillance		Lobectomy .....	182
program for .....	144	Meningococcal infection .....	123
epidemiology of .....	143	antibiotics against .....	126
etiologiical classification of .....	144	anti-sepsis drugs for .....	127
evaluating a child with .....	143	diagnosis of .....	127
evaluation of .....	144	diagnostic test for .....	125
genetic cause of .....	147	host genetic determinants in .....	124
genetic workup on .....	150	in adolescents .....	123
investigations for .....	147	in children .....	123
metabolic tests for .....	148	pathophysiology of .....	123
metabolic workup on .....	151	prophylaxis for .....	126
neuroimaging in .....	148	severity of illness scoring systems of .....	125
neuroimaging workup on .....	151	supportive therapy in pediatric ICU .....	126
Head injury .....	50	treatment for .....	126
Hirschsprung's disease .....	179	vaccination against .....	128
Hyperhidrosis .....	182	Mental retardation (MR) .....	143
Hypoxia/hyperoxia .....	201	approach to child with .....	149
chronic exposure to .....	201	clinical assessment of .....	145

definition of .....	143	hand washing in .....	56
developmental screening/developmental surveillance program for .....	144	health personnel vaccination for .....	59
epidemiology of .....	143	in paediatrics .....	53
etiological classification of .....	144	isolation measures for .....	56
evaluating a child with .....	143	pathogenesis of.....	53
evaluation of .....	144	prevention measures for .....	56
genetic cause of .....	147	rational use of antibiotics in .....	58
genetic workup on .....	150	technological devices for .....	53
investigations for .....	147	types of .....	55
metabolic tests for .....	148	use of gloves/masks/gowns .....	58
metabolic workup on .....	151	Nutritional assessment .....	233
neuroimaging in .....	148	body composition tests in .....	240
neuroimaging workup on .....	151	energy expenditure in .....	239
Mild persistent asthma .....	156	immunity-exercise tolerance in .....	241
by viral induced wheezing .....	159	in critically ill child .....	233
drug therapy for .....	156	indices for .....	236
Minimal access surgery .....	177	malnutrition in .....	233
for children .....	177	protein turnover in .....	236
for infants .....	177	role of anthropometrics .....	235
for repair of tracheo-oesophageal fistula .....	182	Painful scoliosis .....	278
in empyema .....	182	Parapneumonic effusions .....	259
in intersex .....	181	antibiotic therapy for .....	261
in pneumothorax .....	181	definition of .....	260
in thorax .....	181	diagnosis of .....	260
in tumours .....	181	epidemiology of .....	259
range of .....	178	fibrinolytic/surgical therapy for .....	261
Moderate persistent asthma .....	160	management of .....	259
NADPH oxidase .....	64	management of .....	261
function of .....	64	thoracostomy tube insertion for .....	261
structure of.....	64	Parent-adolescent communication .....	370
Neck muscle dysfunction .....	36	Partial developmental delay (ParDD) .....	143
Neisseria meningitidies .....	123	approach to child with .....	149
antibiotics against .....	126	definition of .....	143
bacterial characteristics of .....	124	developmental screening/developmental surveillance program for .....	144
epidemiology of .....	123	epidemiology of .....	143
host genetic determinants in .....	124	evaluating a child with .....	143
pathophysiology of .....	123	genetic workup on .....	150
Neonatal brain damage .....	3	metabolic workup on .....	151
chemokines in .....	3	neuroimaging workup on .....	151
proinflammatory cytokines in .....	3	Perceived family supports .....	371
Neonatal seizures .....	315	Perinatal asphyxia .....	131
for methods for .....	316	by cytosolic calcium .....	137
outcome of newborns with .....	315	by deficiencies in energy supply .....	134
predictors for .....	315	by genes .....	138
risk factors for .....	315	by inflammatory mediators .....	137
Neonates .....	6	by necrosis/apoptosis .....	138
brain damage in .....	6	by nitric oxide .....	136
Nephrectomy .....	181	by reactive oxygen species/free radicals .....	134
Non reversible obstructive airway disease .....	343	by transcription factors activation .....	138
Non-synostotic plagiocephaly .....	33	cellular bases of .....	132
clinical features of .....	33	mechanisms of cellular/tisular lesion in .....	131
determinants of .....	35	Perinatal hypoxic-ischemic brain injury .....	131
measurements/severity scores of.....	34	by cytosolic calcium .....	137
obstetric factors of .....	36	by deficiencies in energy supply .....	134
prevalence and natural history of .....	35	by genes .....	138
prevention of .....	37	by inflammatory mediators .....	137
treatment of .....	36	by necrosis/apoptosis .....	138
Normal developmental EEG .....	19	by nitric oxide .....	136
Nosocomial infections .....	53	by reactive oxygen species/free radicals .....	134
epidemiology of .....	55	by transcription factors activation .....	138

cellular bases of .....	132	Scheuermann's disease .....	270
cellular mechanisms in .....	131	Severe persistent asthma .....	161
excitotoxicity in .....	132	Spondylolysis-spondylolisthesis .....	272
Peripheral respiratory control system .....	199	Studies of .....	343
neuroendocrine programming of .....	199	airway hyperresponsiveness in .....	343
role in neonatal environment .....	199	inflammation in .....	343
Peripheral vascular resistance .....	211	Sympathectomy for .....	182
basic science studies of .....	211	Synthesis .....	369
clinical studies in .....	211	Systemic lupus erythematosus (SLE) .....	165
Polyunsaturated fatty acids .....	107	adjunctive therapies for .....	169
functions of .....	107	anti-CD20 antibody for .....	168
in inflammation .....	107	antologous marrow stem-cell trans	
Preterm infants .....	187	plantation for .....	168
peak inspiratory pressure in .....	188	azathioprine for .....	166
role of neopuff® infant resuscitator .....	189	ciclosporin for .....	167
Primary vesicoureteric reflux .....	173	corticosteroids (CS) for .....	165
bladder dysfunction pattern in children with .....	173	cyclophosphamide (CYC) for .....	166
genetic predisposition of .....	174	human intravenous immunoglobulin (IVIG) for ...	167
management of .....	175	hydroxychloroquine for .....	165
pathogenesis of .....	173	in childhood .....	165
pathogenesis of kidney damage associated with ....	174	methotrexate (MTX) for .....	167
Pulmonary blood flow (PBF) .....	287	mycophenolate mofetil (MMF) for .....	167
after birth .....	287	new therapies for .....	167
in fetus .....	287	non-steriod anti-inflammatory drugs (NSAID) for	165
role of intra-luminal pressure regulating .....	287	prevention of atherosclerosis for .....	169
Pyeloplasty .....	181	psychoeducational intervention for .....	169
Pyloric stenosis .....	179	thalidomide for .....	167
		treatment of growth failure/osteoporosis for .....	169
Quantitative EEG .....	19	treatments for .....	165
		vaccination for .....	169
Reflux nephropathy .....	173	Traditional EEG .....	18
Rehabilitation .....	309	Tuberculous spondylitis .....	278
Renal function .....	225		
endogenous surrogate markers for .....	226	Ventilation .....	187
in children .....	225	preterm infants in delivery room .....	187
nuclear medicine methods to .....	226	Vertebral osteomyelitis .....	277
role of cystatin C .....	225	Vesicoureteric reflux .....	181
Robotic surgery .....	182		